In this exploratory analysis of a population-based screening trial, we report that the use of the Stockholm3 blood test or PSA density for the detection of significant prostate cancer among men with LUTS is superior to the use of PSA solely. This evidence concerns the gene KLK3 and Familial prostate cancer.